FOR IMMEDIATE RELEASE
New Orleans, LA – LaCell LLC and Obatala Sciences, Inc., disruptive biotechnology startups in the field of tissue engineering and regenerative medicine received a grant for $235k on May 1st. The grant was endowed by National Center for Advancing Translational Sciences (NCATS) for the creation of a universal medium that can support the survival of multiple tissues derived from human induced pluripotent stem cells (iPSCs), in a microphysiological system.
“Obatala Sciences is very excited to partner with NCATS to develop this universal medium. The medium will benefit academic laboratories and contract research organizations and contribute to improving models of human disease and response. We thank NCATS for choosing Obatala as their preferred partner and look forward to a continued partnership.”
LaCell LLC was founded in 2010 by Jeffrey Gimble MD Ph.D. and Xiying Wu MD and, together with Trivia Frazier Ph.D., they spun-out and co-founded Obatala Sciences, Inc. in 2017. The companies synergize and focus on creating biotechnology products that advance tissue engineering research and reduce the costs of drug development. Their suite of products and services include adult human primary cells, the first human-derived 3D culture medium. Learn more about Obatala Sciences and LaCell and how to get involved at their websites (obatalasciences.com and lacell-usa.com)